Market news

Glaukos' iDose and Epioxa are driving growth, while recurring treatments, high margins and a broad pipeline support its long-term prospects.

Glaukos (NYSE:GKOS) has outperformed the market over the past 10 years by 1.4% on an annualized basis producing an average annual return of 14.97%. Currently, Glaukos has a market capitalization of $9.57 billion.

ALISO VIEJO, Calif., September 23, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the launch of Could it be KC?, a new disease awareness and educational campaign launching today with expanding activities planned in 2027 aimed at improving recognition and earlier detection of keratoconus (KC), a rare, progressive, sight-threatening

Glaukos (GKOS) slipped about 1% at the last close to $159.86, extending a month-long pullback of roughly 14%, even as the ophthalmic specialist posts annual revenue of $612.8 million. Glaukos shares have cooled off in the short term, with a 7 day share price return down 6.9% and a 30 day share price return down 13.5%. The broader trend is still strong, as the year to date share price return sits at 44.4% and the 1 year total shareholder return is 88.8%, which may indicate that recent weakness...

Tomas Navratil, Chief Development Officer, on August 28, 2026, sold 13,744 shares in Glaukos (GKOS)

Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Glaukos' iDose TR and Epioxa are driving rapid growth, while margin expansion and a broad pipeline strengthen its long-term prospects.

ALISO VIEJO, Calif., August 19, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 9, 2026, at 3:00 p.m. ET in Boston, MA.

Detailed price information for Glaukos Corp (GKOS-N) from The Globe and Mail including charting and trades.

Detailed price information for Glaukos Corp (GKOS-N) from The Globe and Mail including charting and trades.

Detailed price information for Mannkind Corp (MNKD-Q) from The Globe and Mail including charting and trades.

In late July 2026, Glaukos Corporation reported record second-quarter results, with net sales rising to US$185.61 million and a narrower quarterly loss, and raised its 2026 net sales guidance to US$680 million–US$700 million from US$620 million–US$635 million. Alongside the guidance increase, Glaukos completed enrollment in its pivotal U.S. PRESERFLO MicroShunt study, underscoring how expanding clinical programs and strong uptake of products like iDose TR and Epioxa are shaping expectations...

Glaukos (GKOS) just reported record second quarter sales and raised its 2026 net sales guidance to a range of $680 million to $700 million, putting fresh attention on the stock. See our latest analysis for Glaukos. The raised 2026 guidance and record quarter have come alongside sharp share price momentum, with Glaukos posting a 20.6% 1 month share price return and a 52.2% year to date share price return, contributing to a 95.8% 1 year total shareholder return. If this kind of move has your...

Moby summary of Glaukos Corporation's Q2 2026 earnings call

Glaukos (GKOS) has an average rating of buy and mean price target of $185, according to analysts pol

GKOS' Q2 loss narrows as revenues jump 50% on iDose TR and Epioxa growth, lifting its 2026 sales outlook and shares by 9.8%.

Glaukos (GKOS) delivered earnings and revenue surprises of +50.00% and +24.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Glaukos Corp (GKOS) posts a 50% revenue jump to $185.6 million, driven by iDose TR and Epioxa, while navigating LCD challenges and a Q3 corneal health transition.

Although the revenue and EPS for Glaukos (GKOS) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Glaukos: Q2 Earnings Snapshot

ALISO VIEJO, Calif., July 27, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced the completion of patient enrollment in its U.S. 510(k) pivotal study evaluating the PRESERFLO™ MicroShunt in adult patients with primary open-angle glaucoma (POAG) who failed previous medical and surgical treatment.

Detailed price information for Johnson & Johnson (JNJ-N) from The Globe and Mail including charting and trades.

Disposition represented 19% of insider's equity holdings under pre-established Rule 10b5-1 trading plan. Thurman retains 43,681 shares worth approximately $6.77 million.

Detailed price information for Glaukos Corp (GKOS-N) from The Globe and Mail including charting and trades.

GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.

ALISO VIEJO, Calif., July 08, 2026--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, plans to release second quarter 2026 financial results after the market close on Wednesday, July 29, 2026. The company’s management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 29, 2026.

Glaukos stock is in the buy zone of a base. The glaucoma treatment developer raised its revenue forecast in its latest earnings report.